Opinion Paper/CommentaryIs It Time to Introduce PET/CT in Colon Cancer Guidelines?Maffione, Anna Margherita MD∗; Rubello, Domenico MD∗; Caroli, Paola MD†; Colletti, Patrick M. MD‡; Matteucci, Federica MD†Author Information From the ∗Nuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo †Nuclear Medicine Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy ‡Radiology Department, Keck School of Medicine of USC, Los Angeles, CA. Received for publication March 12, 2020; revision accepted March 17, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Anna Margherita Maffione, MD, Department of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy, Viale Tre Martiri, 140, 45100 Rovigo, Italy. E-mail: firstname.lastname@example.org. Clinical Nuclear Medicine: July 2020 - Volume 45 - Issue 7 - p 525-530 doi: 10.1097/RLU.0000000000003076 Buy Metrics Abstract International colon cancer guidelines suggest 18F-FDG PET/CT in a few circumstances: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma; (2) in the workup of recurrent colon cancer with metachronous metastases documented by CT, MRI, or biopsy and in case of serial CEA elevation with negative colonoscopy and negative CT; and (3) in case of contraindication to iodine- and gadolinium-based contrast agents. However, review of the literature has shown that PET/CT can also be used in other scenarios with significant levels of diagnostic advantage. This review aims to emphasize differences between guidelines and scientific literature for the use of PET/CT in colon cancer. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.